Identity
- Security key
- 22692
- Ticker
- TPST
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2021-06-28
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- TPST
Detail
Enriched 2026-08-14 20:47
- Market cap
- $19,335,087.31
- Shares outstanding (class)
- 15,979,411
- Shares outstanding (weighted)
- 15,979,411
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 4
- Location
- BRISBANE, CA
- Homepage
- https://www.tempesttx.com
- Description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.